These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 30799262)

  • 21. Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.
    Kwong A; Wong CH; Suen DT; Co M; Kurian AW; West DW; Ford JM
    World J Surg; 2012 Apr; 36(4):702-13. PubMed ID: 22290208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
    Ståhlbom AK; Johansson H; Liljegren A; von Wachenfeldt A; Arver B
    Fam Cancer; 2012 Mar; 11(1):33-40. PubMed ID: 22124624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients.
    Kang E; Park SK; Yang JJ; Park B; Lee MH; Lee JW; Suh YJ; Lee JE; Kim HA; Oh SJ; Kim SW;
    Breast Cancer Res Treat; 2012 Aug; 134(3):1189-97. PubMed ID: 22438049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
    MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
    Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selecting a BRCA risk assessment model for use in a familial cancer clinic.
    Panchal SM; Ennis M; Canon S; Bordeleau LJ
    BMC Med Genet; 2008 Dec; 9():116. PubMed ID: 19102775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
    J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of risk prediction models in breast cancer screening among women in Cyprus.
    Danladi C; Serakinci N
    East Mediterr Health J; 2022 Dec; 28(12):888-895. PubMed ID: 36573569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).
    Zeinomar N; Knight JA; Genkinger JM; Phillips KA; Daly MB; Milne RL; Dite GS; Kehm RD; Liao Y; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; ; Andrulis IL; Buys SS; John EM; MacInnis RJ; Hopper JL; Terry MB
    Breast Cancer Res; 2019 Nov; 21(1):128. PubMed ID: 31779655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations.
    Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA;
    Hum Reprod; 2016 May; 31(5):1126-32. PubMed ID: 27094481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
    Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
    Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.
    Roudgari H; Miedzybrodzka ZH; Haites NE
    Fam Cancer; 2008; 7(3):199-212. PubMed ID: 18097771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Estimation of individual breast cancer risk: relevance and limits of risk estimation models].
    De Pauw A; Stoppa-Lyonnet D; Andrieu N; Asselain B
    Bull Cancer; 2009 Oct; 96(10):979-88. PubMed ID: 19744918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification.
    Pal Choudhury P; Wilcox AN; Brook MN; Zhang Y; Ahearn T; Orr N; Coulson P; Schoemaker MJ; Jones ME; Gail MH; Swerdlow AJ; Chatterjee N; Garcia-Closas M
    J Natl Cancer Inst; 2020 Mar; 112(3):278-285. PubMed ID: 31165158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
    Kurian AW; Gong GD; John EM; Miron A; Felberg A; Phipps AI; West DW; Whittemore AS
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1084-91. PubMed ID: 19336551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of the BOADICEA model in a prospective cohort of
    Yang X; Mooij TM; Leslie G; Ficorella L; Andrieu N; Kast K; Singer CF; Jakubowska A; van Gils CH; Tan YY; Engel C; Adank MA; van Asperen CJ; Ausems MGEM; Berthet P; ; Collee MJ; Cook JA; Eason J; Spaendonck-Zwarts KYV; Evans DG; Gómez García EB; Hanson H; Izatt L; Kemp Z; Lalloo F; Lasset C; Lesueur F; Musgrave H; Nambot S; Noguès C; Oosterwijk JC; Stoppa-Lyonnet D; Tischkowitz M; Tripathi V; Wevers MR; Zhao E; van Leeuwen FE; Schmidt MK; Easton DF; Rookus MA; Antoniou AC
    J Med Genet; 2024 Jul; 61(8):803-809. PubMed ID: 38834293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results.
    MacInnis RJ; Liao Y; Knight JA; Milne RL; Whittemore AS; Chung WK; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; McLachlan SA; Weideman PC; Nesci S; Friedlander ML; Glendon G; ; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB
    J Natl Cancer Inst; 2020 Apr; 112(4):418-422. PubMed ID: 31584660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.
    Kurian AW; Hughes E; Simmons T; Bernhisel R; Probst B; Meek S; Caswell-Jin JL; John EM; Lanchbury JS; Slavin TP; Wagner S; Gutin A; Rohan TE; Shadyab AH; Manson JE; Lane D; Chlebowski RT; Stefanick ML
    Cancer; 2021 Oct; 127(20):3742-3750. PubMed ID: 34228814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.